G. Bodoky

发表

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

E. Van Cutsem, G. D'Haens, R. Lim, 2009, The New England journal of medicine.

Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

R. Greil, R. Labianca, L. Collette, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2013, The New England journal of medicine.

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Masatoshi Kudo, Osamu Yokosuka, Gianluca Masi, 2017, The Lancet.

Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).

R. Winterhalder, G. Bodoky, K. Zaugg, 2018, European journal of cancer.

O-0003NAPOLI-1: RANDOMIZED PHASE 3 STUDY OF MM-398 (NAL-IRI), WITH OR WITHOUT 5-FLUOROURACIL AND LEUCOVORIN, VERSUS 5-FLUOROURACIL AND LEUCOVORIN, IN METASTATIC PANCREATIC CANCER PROGRESSED ON OR FOLLOWING GEMCITABINE-BASED THERAPY

David Cunningham, G. Bodoky, D. Cunningham, 2014 .

In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity

B. Győrffy, B. Ács, G. Bodoky, 2016, Diagnostic Pathology.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

J Ricke, T Maughan, W. Oyen, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.

W. Scheithauer, R. Herrmann, T. Ruhstaller, 2008, The Lancet. Oncology.

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Sabine Tejpar, Mauro Delorenzi, Dirk Klingbiel, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of fasting, intermittent feeding, or continuous parenteral nutrition on rat liver and brain energy metabolism as assessed by 31P-NMR

N. Szeverenyi, G. Bodoky, A. Laviano, 1995, Physiology & Behavior.

The comparative effects of abrupt vs. stepwise discontinuation of TPN in rats

G. Bodoky, M. Meguid, D. Hitch, 1992, Physiology & Behavior.

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.

R. Labianca, D. Kerr, I. Nagtegaal, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

R. Salazar, E. Van Cutsem, G. Bodoky, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

E. Van Cutsem, J. Tabernero, Tae Won Kim, 2015, The Lancet. Oncology.

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study

E. Van Cutsem, J. Tabernero, A. Grothey, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Exposure–response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial

E. Van Cutsem, J. Tabernero, V. Heinemann, 2017, Cancer Chemotherapy and Pharmacology.

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression†

E. Van Cutsem, J. Tabernero, T. Ciuleanu, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.

D. Kerr, J. Hainsworth, J. Hecht, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blood supply of metastatic hepatic tumors: suggestions for improved delivery of chemotherapeutic agents.

J. Tímár, G. Bodoky, P. Kupcsulik, 1998, Journal of the National Cancer Institute.

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Josep Tabernero, Jean-Yves Douillard, David Cunningham, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial

J. Tabernero, J. Canon, G. Bodoky, 2016, ESMO Open.

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

R. Labianca, R. Schilsky, J. Berlin, 2018, European journal of cancer.

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.

J. Bruix, R. Finn, O. Yokosuka, 2018, Journal of hepatology.

Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores

W. Scheithauer, R. Herrmann, S. Pignata, 2019, Therapeutic advances in medical oncology.

Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.

A. Carrato, M. Buyse, J. Ajani, 2013, European journal of cancer.

Tumor response and symptom palliation from RAINBOW, a phase 3 trial of ramucirumab plus paclitaxel in previously treated advanced gastric cancer.

J. Ajani, E. Van Cutsem, G. Bodoky, 2020, The oncologist.

Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy

W. Scheithauer, J. Bernhard, G. Bodoky, 2010, British Journal of Cancer.

A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1)

J. Hainsworth, J. Hecht, R. Wolff, 2005 .

Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer

G. Bodoky, D. Cunningham, Chung-Pin Li, 2019, Pancreas.

Effects of different types of isocaloric parenteral nutrients on food intake and metabolic concomitants

G. Bodoky, A. Laviano, M. Meguid, 1995, Physiology & Behavior.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Effect of enteral nutrition on exocrine pancreatic function.

G. Bodoky, T. Tihanyi, L. Harsányi, 1991, American journal of surgery.

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.

J. Ajani, M. Shah, E. Van Cutsem, 2017, The Lancet. Oncology.

Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).

J. Dufour, G. Bodoky, M. Montemurro, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Benefit Response in Pancreatic Cancer Trials Revisited

W. Scheithauer, R. Herrmann, J. Bernhard, 2014, Oncology Research and Treatment.

Final results of a randomized, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks (Q3W) for the treatment of anemia in patients receiving multicycle chemotherapy

J. Canon, G. Bodoky, J. Vansteenkiste, 2005 .

[Pharmacologic therapy for neuroendocrine tumours].

G. Bodoky, Á. Petrányi, György Bodoky, 2011, Orvosi hetilap.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses.

J. Ajani, G. Bodoky, M. Lichinitser, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3)

R. Labianca, B. Nordlinger, G. Bodoky, 2005 .

3013 ORAL Tissue biomarkers in colon cancer (COC): Early results of the translational study on a phase III trial comparing infused irinotecan/ 5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II–III COC patients (PETACC 3–EORTC 40993–SAKK 60/00)

R. Labianca, G. Bodoky, S. Tejpar, 2007 .

Tissue biomarkers (BIOM) in colon cancer (COC): The translational study on the randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II-III COC patients (pts)

R. Labianca, G. Bodoky, S. Tejpar, 2007 .

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Naotoshi Sugimoto, Yasuhiro Shimada, David Ferry, 2014, The Lancet. Oncology.

Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.

J. Ajani, E. Van Cutsem, G. Bodoky, 2020, European journal of cancer.

Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer

J. Ajani, C. Fuchs, E. Van Cutsem, 2017, Molecular Cancer Therapeutics.

Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer.

J. Ajani, C. Fuchs, J. Tabernero, 2015 .

D04Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer

J. Tabernero, T. Ciuleanu, G. Bodoky, 2016 .

O-007Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

J. Ajani, G. Bodoky, Z. Wainberg, 2016 .

2123 Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer

J. Tabernero, T. Ciuleanu, G. Bodoky, 2015 .

Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naïve patients with advanced pancreatic cancer (APC).

H. Friess, Y. Humblet, G. Bodoky, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): Outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial.

E. Van Cutsem, R. Lim, C. Stroh, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy

G. Bodoky, J. Douillard, A. Awada, 2020, ESMO Open.

Quality of life (QoL) during first-line treatment with FOLFOX4 with or without panitumumab (pmab) in RAS wild-type (WT) metastatic colorectal carcinoma (mCRC).

J. Tabernero, J. Canon, G. Bodoky, 2015 .

Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG)

W. Scheithauer, R. Herrmann, J. Bernhard, 2005 .

741P Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone.

G. Bodoky, D. Cunningham, F. Braiteh, 2017 .

Nocturnal cyclic versus continuous total parenteral nutrition: Food intake and feeding pattern in rats

G. Bodoky, M. Meguid, Zhongjin Yang, 1992, Physiology and Behavior.

The method of early postoperative alimentation by needle-catheter jejunostomy.

G. Bodoky, L. Harsányi, 1989, Acta chirurgica Hungarica.

Cetuximab in Combination with Capecitabine and Cisplatin as First-Line Treatment in Advanced Gastric Cancer: Randomized Controlled Phase III Expand Study

F. Lordick, G. Bodoky, S. Oh, 2012 .

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Yan-Shen Shan, Paul Ross, Daniel Palmer, 2016, The Lancet.

3001 ORAL CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC)

P. Lebrun, F. Ciardiello, J. Roh, 2007 .

Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study.

Joon-Oh Park, F. Lordick, Yoon-Koo Kang, 2013 .

Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma (HCC): A multicenter phase II trial (SAKK 77/06 and SASL 23).

G. Bodoky, M. Montemurro, P. Majno, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of modified (m)RECISTand RECIST 1.1 assessments in the phase 3 RESORCE trial comparing regorafenib and placebo in patients with hepatocellular carcinoma who progressed during sorafenib treatment

M. Kudo, J. Bruix, G. Bodoky, 2017 .

Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial

M. Kudo, J. Bruix, O. Yokosuka, 2016 .

Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial

J. Bruix, P. Galle, R. Finn, 2017, Zeitschrift für Gastroenterologie.

LBA-03Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial

M. Kudo, J. Bruix, O. Yokosuka, 2016 .

Current therapy of advanced colorectal cancer according to RAS/RAF mutational status

C. Köhne, G. Bodoky, G. Lakatos, 2020, Cancer and Metastasis Reviews.

1021 GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HEPATOCELLULAR CARCINOMA (HCC) AND OF ITS TREATMENT WITH SORAFENIB (GIDEON): IMPACT OF LIVER DYSFUNCTION ON SORAFENIB TREATMENT IN EUROPE

B. Daniele, G. Bodoky, A. Croitoru, 2012 .

Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab

E. Van Cutsem, Y. Humblet, G. Bodoky, 2007, British Journal of Cancer.

Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.

M. Kudo, J. Bruix, O. Yokosuka, 2018 .

ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology.

G. Bodoky, F. Bozzetti, M. Muscaritoli, 2006, Clinical nutrition.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.

W. Scheithauer, R. Herrmann, J. Bernhard, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).

G. Bodoky, M. Montemurro, M. Borner, 2010, The oncologist.

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.

J. Hecht, R. Salazar, E. Van Cutsem, 2012, The Lancet. Oncology.

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.

Galina Kurteva, Yoon-Koo Kang, Heiko Götte, 2013, The Lancet. Oncology.

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

T. Ciuleanu, G. Bodoky, N. Tebbutt, 2012, Investigational New Drugs.

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data

C. Fuchs, E. Van Cutsem, H. Safran, 2017, Journal of gastric cancer.

Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.

P. Hegyi, G. Bodoky, L. Harsányi, 2017, Pathology & Oncology Research.

Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement.

B. Sikic, J. Jassem, R. Pirker, 2016, The oncologist.

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma†

Y. Shimada, E. Van Cutsem, N. Sugimoto, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Current therapy of advanced colorectal cancer according to RAS/RAF mutational status

C. Köhne, G. Bodoky, G. Lakatos, 2020, Cancer and Metastasis Reviews.

Tricellulin expression in normal and neoplastic human pancreas

G. Bodoky, A. Kiss, I. Kenessey, 2012, Histopathology.

Cancer epidemiology in Central and South Eastern European countries

G. Bodoky, A. Croitoru, M. Wojtukiewicz, 2011, Croatian medical journal.

Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set

D. Mytelka, E. Van Cutsem, J. Tabernero, 2018, ESMO Open.

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.

J. Ajani, G. Bodoky, M. Lichinitser, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.

A. Carrato, L. Lipton, C. Fuchs, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.

E. Van Cutsem, G. Bodoky, M. Bass, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)

J. Ajani, M. Shah, G. Bodoky, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.

G. Bodoky, D. Cunningham, Chung-Pin Li, 2018, European journal of cancer.

Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial.

D. Jäger, G. Bodoky, W. Bechstein, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

The Activated Targets of mTOR Signaling Pathway Are Characteristic for PDGFRA Mutant and Wild-type Rather Than KIT Mutant GISTs

G. Bodoky, Z. Sápi, L. Moskovszky, 2011, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results

G. Bodoky, A. Maráz, M. Dank, 2017, Pathology & Oncology Research.

Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW

C. Fuchs, E. Van Cutsem, J. Tabernero, 2018, Journal of gastroenterology and hepatology.

Consensus on the medical treatment of colon cancer

W. Scheithauer, T. Gruenberger, J. Tabernero, 2008 .

Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.

J. Canon, G. Bodoky, J. Vansteenkiste, 2006, Journal of the National Cancer Institute.

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.

S. Reingold, W. Scheithauer, E. Van Cutsem, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

T. Ciuleanu, G. Bodoky, N. Tebbutt, 2012, Investigational New Drugs.

Re: Alcohol Dehydrogenase 3 Genotype and Risk of Oral Cavity and Pharyngeal Cancers

G. Bodoky, P. Kupcsulik, S. Paku, 1998 .

Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

G. Bodoky, L. Geczi, L. Torday, 2020, Pathology & Oncology Research.

Ef ﬁ cacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

J. Jassem, J. Canon, Y. Humblet, 2014 .

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014 .

The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma

G. Bodoky, I. Láng, S. Eckhardt, 2000, Cancer.

A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine.

A. V. Pavlovsky, T. Ciuleanu, G. Bodoky, 2009, European journal of cancer.

Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.

W. Scheithauer, R. Herrmann, J. Bernhard, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

E. Van Cutsem, J. Tabernero, T. Ciuleanu, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

The prognostic value of baseline neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398) + 5-fluorouracil and leucovorin (5-FU/

G. Bodoky, D. Cunningham, Chung-Pin Li, 2017 .

[Effect of imatinib treatment of gastrointestinal stromal tumors].

G. Bodoky, J. Horti, L. Trón, 2003, Orvosi hetilap.

Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer

E. Rock, E. Van Cutsem, B. Melichar, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.

W. Miller, D. Haller, G. Bodoky, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Medical Oncology Workload in Europe: One Continent, Several Worlds.

M. Brundage, G. Bodoky, R. Sullivan, 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1).

J. Ajani, M. Shah, G. Bodoky, 2019, Journal of Clinical Oncology.

Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial

J. Bruix, O. Yokosuka, G. Bodoky, 2017, Zeitschrift für Gastroenterologie - German Journal of Gastroenterology.

Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma

M. Fassan, G. Bodoky, A. Kiss, 2014, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS)

A. Carrato, J. Ajani, J. Jassem, 2015, Journal of Gastrointestinal Cancer.

Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.

J. Tabernero, Tae Won Kim, T. Ciuleanu, 2017, European journal of cancer.

Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe.

B. Sikic, J. Jassem, R. Pirker, 2018, The oncologist.

Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.

R. Winterhalder, G. Bodoky, F. Bosman, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo

J. Bruix, O. Yokosuka, G. Bodoky, 2017, Zeitschrift für Gastroenterologie.

Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib

M. Kudo, J. Bruix, O. Yokosuka, 2018, Zeitschrift für Gastroenterologie.

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).

Scott D. Patterson, Josep Tabernero, Jean-Yves Douillard, 2013 .

A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial.

R. Salazar, E. Van Cutsem, J. Tabernero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rectal Cancer Therapy: Decision Making on Basis of Quality of Life?*

G. Bodoky, J. Weltner, M. Borsodi, 2004, Zentralblatt fur Chirurgie.

RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results.

Tae-You Kim, N. Sugimoto, G. Bodoky, 2014 .

Rationale and design of the PROMETCO study: a real-world, prospective, longitudinal cohort on the continuum of care of metastatic colorectal cancer from a clinical and patient perspective.

G. Bodoky, M. Koopman, C. Pinto, 2022, Future oncology.

Cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: A phase II trial.

G. Bodoky, M. Lutz, C. Lilla, 2016, Journal of Clinical Oncology.

Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial.

D. Jäger, G. Bodoky, W. Bechstein, 2012 .

[ON ACUTE PNEUMO-CHOLECYSTITIS].

G. Bodoky, I. Koeves, G. Foeldvari, 1963, Orvosi hetilap.

O-020Quality-of-life results from RAISE: randomized, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine

T. Ciuleanu, G. Bodoky, P. Rougier, 2015 .

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer

E. Van Cutsem, V. Heinemann, G. Bodoky, 2023, ESMO open.

Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

G. Bodoky, D. Cunningham, E. Bayever, 2016 .

Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study.

B. Daniele, G. Bodoky, A. Croitoru, 2015, Future oncology.

The effect of jejunal nutrition on pancreatic exocrine function.

G. Bodoky, L. Harsányi, Á. Pap, 1992, Acta chirurgica Hungarica.

Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-ras unmutated, locally advanced rectal cancer (LARC): Final results of a randomized multicenter phase II trial (SAKK 41/07).

R. Winterhalder, G. Bodoky, F. Bosman, 2015 .

Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.

G. Bodoky, D. Cunningham, E. Bayever, 2015 .

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

W. Oyen, R. Labianca, W. Scheithauer, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

M. Kudo, J. Bruix, J. Llovet, 2017, The Lancet.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).

J. Dufour, G. Bodoky, M. Montemurro, 2016, Annals of Oncology.

P PROGNOSIS IMPACT OF POSTOPERATIVE RADIATION IN PATIENTS WITH RADICAL ESOPHAGECTOMY AND PATHOLOGIC LYMPH NODES POSITIVE ESOPHAGEAL CANCER

J. Reis-Filho, M. Borad, D. Ryan, 2012 .

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Joon-Oh Park, K. Rau, C. Sternberg, 2016, The Lancet.

J. Ajani, G. Bodoky, M. Lichinitser, 2013, European journal of cancer.

Breast cancer, early stage

M. Espié, C. Mermel, R. Gelber, 2012 .